# A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

> **NCT02681237** · NA · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 34 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Cediranib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02681237
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-29
- **Primary completion:** 2022-01-10
- **Final completion:** 2022-03-25
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681237, "A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02681237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*